Top Markets
#1 ONFA ONFA +225.76%
#2 Resolv wstUSR Resolv wstUSR +198.02%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +38.13%
#6 NKN NKN +36.26%
#7 StakeStone StakeStone +28.59%
#8 BLOCKv BLOCKv +26.08%
#9 KONET KONET +24.91%
#10 OpenVPP OpenVPP +22.33%
Coin of the day
ONFA ONFA
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Pozycja w akcjach #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Cena akcji
$0.5275
Kapitalizacja rynkowa
$1.25M
Zmiana (1 dzień)
-3.56%
Zmiana (1 rok)
-83.77%
Kraj
US
Handel Ensysce Biosciences, Inc. (ENSC)

Kategoria

Healthcare
Zyski dla Ensysce Biosciences, Inc. (ENSC)
Zyski w Sep 2025 TTM: $-10.97M
Według najnowszych raportów finansowych Ensysce Biosciences, Inc., obecny zysk firmy wynosi $-10.97M. W roku 2023 firma osiągnęła zysk w wysokości $-10.63M, wzrost w porównaniu do zysku z roku 2022, który wynosił $-24.21M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Ensysce Biosciences, Inc. od 2017 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
2026 (TTM) $-10.97M 37.39%
2024 $-7.99M -24.84%
2023 $-10.63M -56.10%
2022 $-24.21M -16.94%
2021 $-29.15M 18,017.11%
2020 $-160.88K -98.41%
2019 $-10.10M -477.51%
2018 $2.68M -9,810.43%
2017 $-27.56K 0.00%
Zyski podobnych firm lub konkurentów
Firma Zyski Różnica w zyskach Kraj
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
$20.46B -186,530.54%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$4.64B -42,414.51%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
$5.23B -47,768.53%
US
UCB SA UCB SA
UCB SA
UCB.BR
$2.14B -19,581.29%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -14,811.33%
AU